Liraglutide-Induced Hepatotoxicity

A 52-year-old woman with a BMI of 31.2 kg/m(2) was treated with the glucagon-like peptide 1 (GLP-1) agonist liraglutide as part of her weight-reduction program. Following this, she developed an idiosyncratic drug-related liver injury (IDILI). Advances in noninvasive techniques enabled this diagnosis...

Descripción completa

Detalles Bibliográficos
Autores principales: Maor, Yaakov, Ergaz, David, Malnick, Stephen D. H., Melzer, Ehud, Neuman, Manuela G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7911918/
https://www.ncbi.nlm.nih.gov/pubmed/33498980
http://dx.doi.org/10.3390/biomedicines9020106
_version_ 1783656454836715520
author Maor, Yaakov
Ergaz, David
Malnick, Stephen D. H.
Melzer, Ehud
Neuman, Manuela G.
author_facet Maor, Yaakov
Ergaz, David
Malnick, Stephen D. H.
Melzer, Ehud
Neuman, Manuela G.
author_sort Maor, Yaakov
collection PubMed
description A 52-year-old woman with a BMI of 31.2 kg/m(2) was treated with the glucagon-like peptide 1 (GLP-1) agonist liraglutide as part of her weight-reduction program. Following this, she developed an idiosyncratic drug-related liver injury (IDILI). Advances in noninvasive techniques enabled this diagnosis to be established. By employing easily quantifiable methods based on serum biomarkers, we could explore a wide variety of endpoints in assessing personalized DILI. In addition, we can test endpoints that are associated with the drug’s mechanism of action. Personalized medicine and therapeutic pharmacovigilance of incretin-based hypoglycemic agents are needed to ensure the safety of patients.
format Online
Article
Text
id pubmed-7911918
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-79119182021-02-28 Liraglutide-Induced Hepatotoxicity Maor, Yaakov Ergaz, David Malnick, Stephen D. H. Melzer, Ehud Neuman, Manuela G. Biomedicines Article A 52-year-old woman with a BMI of 31.2 kg/m(2) was treated with the glucagon-like peptide 1 (GLP-1) agonist liraglutide as part of her weight-reduction program. Following this, she developed an idiosyncratic drug-related liver injury (IDILI). Advances in noninvasive techniques enabled this diagnosis to be established. By employing easily quantifiable methods based on serum biomarkers, we could explore a wide variety of endpoints in assessing personalized DILI. In addition, we can test endpoints that are associated with the drug’s mechanism of action. Personalized medicine and therapeutic pharmacovigilance of incretin-based hypoglycemic agents are needed to ensure the safety of patients. MDPI 2021-01-22 /pmc/articles/PMC7911918/ /pubmed/33498980 http://dx.doi.org/10.3390/biomedicines9020106 Text en © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Maor, Yaakov
Ergaz, David
Malnick, Stephen D. H.
Melzer, Ehud
Neuman, Manuela G.
Liraglutide-Induced Hepatotoxicity
title Liraglutide-Induced Hepatotoxicity
title_full Liraglutide-Induced Hepatotoxicity
title_fullStr Liraglutide-Induced Hepatotoxicity
title_full_unstemmed Liraglutide-Induced Hepatotoxicity
title_short Liraglutide-Induced Hepatotoxicity
title_sort liraglutide-induced hepatotoxicity
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7911918/
https://www.ncbi.nlm.nih.gov/pubmed/33498980
http://dx.doi.org/10.3390/biomedicines9020106
work_keys_str_mv AT maoryaakov liraglutideinducedhepatotoxicity
AT ergazdavid liraglutideinducedhepatotoxicity
AT malnickstephendh liraglutideinducedhepatotoxicity
AT melzerehud liraglutideinducedhepatotoxicity
AT neumanmanuelag liraglutideinducedhepatotoxicity

Ejemplares similares